Which vaccines are recommended for administration to a child at their 2-month well-child visit.

Choice A rationale Rotavirus (RV) vaccine, which prevents severe diarrhea and vomiting caused by the rotavirus, is one of the recommended vaccines for routine administration at the 2-month well-child visit. It is an oral vaccine series, and the first dose is typically given between 6 and 14 weeks of age. Choice B rationale Tetanus, diphtheria, pertussis (Tdap) is a booster vaccine formulated for adolescents and adults. The primary series given to children uses the DTaP formulation, which contains a higher concentration of the diphtheria toxoid, and the first dose of this series is recommended at 2 months of age. Choice C rationale The Diphtheria, tetanus, pertussis (DTaP) vaccine, which protects against these three serious bacterial diseases, is a standard component of the 2-month well-child visit. This is the first dose of the primary series given to infants and young children. Choice D rationale Hepatitis A (HepA) vaccine series typically begins at 12 to 23 months of age, with the second dose given 6 to 18 months later. It is not generally recommended for administration during the 2-month well-child visit. Choice E rationale The Measles, mumps, rubella (MMR) vaccine series is generally initiated at 12 to 15 months of age, with a second dose given between 4 and 6 years of age. It is not recommended for routine administration at the 2-month well-child visit. Choice F rationale The Haemophilus influenzae type B (HIB) vaccine, which prevents serious invasive bacterial infections like meningitis and epiglottitis, is recommended for the first dose of the primary series at the 2-month well-child visit. Choice G rationale The Pneumococcal conjugate vaccine (PCV), which protects against serious diseases caused by Streptococcus pneumoniae bacteria, such as pneumonia and meningitis, is recommended for the first dose of the primary series at the 2-month well-child visit. Choice H rationale Varicella (VAR) vaccine, which protects against chickenpox, is a live attenuated vaccine typically administered as the first dose at 12 to 15 months of age. It is not routinely recommended for administration at the 2-month well-child visit.